Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06642571 | A Research Study to Compare How Much of the Medicine NNC0519-0130 is in the Blood of People With Overweight or Obesity Who Receive 2 Preparations of the Medicine | PHASE1 | COMPLETED | 46 | — | — | Oct 15, 2024 | May 31, 2025 | Nov 25, 2025 | 1 | United States |
Measured in hours\*nanomoles per liter (h\*nmol/L).
| Arm | Type | Description |
|---|---|---|
| Part 1a: NNC0519-0130 C and NNC0519-0130 B | EXPERIMENTAL | Participants will start treatment with formulation NNC0519-0130 C and receive a pre-determined dose escalation regimen of NNC0519-0130 B and NNC0519-0130 C. |
| Part 1b: NNC0519-0130 B and NNC0519-0130 C | EXPERIMENTAL | Participants will start treatment with formulation NNC0519-0130 B and receive a pre-determined dose escalation regimen of NNC0519-0130 B and NNC0519-0130 C. |
| Part 2a: NNC0519-0130 B and NNC0519-0130 C | EXPERIMENTAL | Participants will receive a pre-determined dose escalation regimen of NNC0519-0130 B in run-in period followed by treatment with NNC0519-0130 B then NNC0519-0130 C. |
| Part 2b: NNC0519-0130 C and NNC0519-0130 B | EXPERIMENTAL | Participants will receive a pre-determined dose escalation regimen of NNC0519-0130 B in run-in period followed by treatment with NNC0519-0130 C then NNC0519-0130 B. |
| Name | Type | Description |
|---|---|---|
| NNC0519-0130 B | DRUG | NNC0519-0130 B will be administered subcutaneously. |
| NNC0519-0130 C | DRUG | NNC0519-0130 C will be administered subcutaneously. |
Inclusion Criteria: * Male or female of non-childbearing potential. * Age 18-64 years (both inclusive) at the time of signing the informed consent. * Body Mass Index (BMI) between 27.0 kilogram per square meter (kg/m\^2) and 39.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to ex...